Shannon Thyme Klinger Sells 1,418 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shannon Thyme Klinger also recently made the following trade(s):

• On Tuesday, September 3rd, Shannon Thyme Klinger sold 114 shares of Moderna stock. The shares were sold at an average price of $76.99, for a total value of $8,776.86.

Moderna Price Performance

Shares of MRNA traded up $1.20 during midday trading on Monday, hitting $44.26. The company’s stock had a trading volume of 6,740,633 shares, compared to its average volume of 4,892,647. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47. The stock has a market capitalization of $17.03 billion, a price-to-earnings ratio of -7.40 and a beta of 1.69. The company’s fifty day simple moving average is $52.38 and its two-hundred day simple moving average is $90.84.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.39) earnings per share. As a group, equities analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its position in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC increased its position in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after acquiring an additional 178,115 shares during the period. Wellington Management Group LLP raised its stake in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after purchasing an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after purchasing an additional 178,939 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on MRNA. The Goldman Sachs Group cut their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. Barclays cut their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Finally, JPMorgan Chase & Co. lowered their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $83.33.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.